Noveltreat 2.4mg/0.75ml Pen

Noveltreat 2.4 mg/0.75 ml Pen contains Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist used to improve blood sugar control in adults with type 2 diabetes and, in appropriate doses and indications, to support chronic weight management alongside diet and exercise. It works by mimicking a natural gut hormone that increases insulin release when blood sugar is high, reduces glucagon secretion, slows stomach emptying, and decreases appetite. These actions help lower blood glucose levels, improve glycemic control, and promote gradual weight loss. Semaglutide is given as a once-weekly subcutaneous injection and should be used exactly as prescribed by a healthcare professional. It is not intended for type 1 diabetes or for the treatment of diabetic ketoacidosis.

Noveltreat Pen contains Semaglutide, a long-acting GLP-1 receptor agonist that supports blood sugar control and weight management. It mimics the body's natural GLP-1 hormone, stimulating insulin release only when blood glucose levels are elevated while reducing glucagon secretion from the pancreas. This helps lower fasting and post-meal blood sugar without causing excessive insulin release during normal glucose levels. Semaglutide also slows gastric emptying, reducing rapid glucose absorption after meals, and acts on appetite centers in the brain to increase satiety and decrease food intake, promoting gradual weight loss. These combined effects improve HbA1c, support metabolic health, and may reduce cardiovascular risk in appropriate patients with type 2 diabetes.

Regular use alongside a balanced diet, physical activity, and ongoing medical supervision helps achieve better long-term glycemic control, weight reduction, and improved overall health. Treatment should always follow the prescribed dosing schedule to minimize gastrointestinal side effects.

Precaution

• Use only under medical supervision.
• Not recommended for type 1 diabetes or diabetic ketoacidosis.
• Inform your doctor if you have a history of pancreatitis, severe gastrointestinal disease, diabetic eye disease, kidney disease, or thyroid disorders.
• Avoid use in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) unless specifically advised otherwise.
• Monitor blood sugar regularly, especially if taking insulin or sulfonylureas.
• Consult your doctor before use during pregnancy or breastfeeding.

Storage

• Store unopened pens in a refrigerator at 2°C–8°C.
• Do not freeze.
• After first use, store as directed in the product labeling (typically refrigerated or at room temperature within the manufacturer's recommended limits).
• Protect from direct heat and sunlight.
• Keep the pen cap on when not in use.
• Keep out of reach of children.